Search / Trial NCT00000715

A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of February 21, 2024

Completed

Keywords

Trimethoprim Sulfamethoxazole Combination Aids Related Opportunistic Infections Pneumonia, Pneumocystis Carinii Pentamidine Infusions, Intravenous Administration, Inhalation Aerosols Acquired Immunodeficiency Syndrome Sulfamethoxazole Trimethoprim

Description

New treatments are needed for PCP, a common lung infection in patients with AIDS, because many patients treated with the two standard treatments, PEN given by injections and SMX/TMP, have had adverse effects that required a change in treatment. There is also a high relapse rate after the standard treatments. Preliminary experiments in humans suggest that aerosolized PEN is as effective as the standard treatments for PCP, and causes few adverse effects. Patients entered in the study are randomly assigned to aerosolized PEN or to intravenous SMX/TMP, for a 21-day trial. SMX/TMP is given 4 ti...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Prior Medication:
  • Allowed:
  • Zidovudine (AZT), but must be suspended during study medication.
  • Unequivocal diagnosis of Pneumocystis carinii pneumonia established by morphologic confirmation of three or more typical Pneumocystis carinii organisms in sputum, bronchoalveolar lavage fluid, or lung tissue obtained by transbronchial or open-lung biopsy within 3 days before or after randomization. If morphologic confirmation is not possible prior to therapy, patients may be randomized if the investigator believes there is a high suspicion of PCP based on clinical presentation. If morphologic diagnosis cannot be established within 5 days of randomization, the patient will be withdrawn from study therapy. Resting (A-a) DO2 less than 30 torr on room air at all ACTG sites except San Francisco General Hospital. Non-ACTG sites will enter patients up to a resting (A-a) DO2less than 55 mmHg on room air.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following are excluded:
  • Dyspnea, cough, bronchospasm, or other reasons causing inability to cooperate with aerosol administration.
  • History of major adverse reaction to pentamidine or sulfonamide-containing preparation defined as:
  • Absolute neutropenia of 750 or less PMN + bands cells/mm3.
  • Thrombocytopenia below 40000 platelets/mm3.
  • Rise in creatinine:
  • To more than 3.0 mg/dl.
  • Liver function abnormalities:
  • SGOT or SGPT greater than 5 x upper limit of normal.
  • Hypoglycemia below 50 mg/dl.
  • Rash:
  • Exfoliative or mucositis.
  • Cough:
  • Unremitting or bronchospasm uncontrolled by bronchodilator preventing more than 50 percent of delivered dose for more than 2 days.
  • Concurrent Medication:
  • Excluded:
  • Other drugs for the treatment or prevention of AIDS or Pneumocystis carinii pneumonia.
  • Zidovudine (AZT).
  • Patients with the following are excluded:
  • Dyspnea, cough, bronchospasm, or other reasons causing inability to cooperate with aerosol administration.
  • History of major adverse reaction to pentamidine or sulfonamide-containing preparation defined as:
  • Absolute neutropenia of 750 or less PMN + bands cells/mm3.
  • Thrombocytopenia lower than 40000 platelets/mm3.
  • Rise in creatinine:
  • To greater than 3.0 mg/dl.
  • Liver function abnormalities:
  • SGOT or SGPT greater than 5 x upper limit of normal.
  • Hypoglycemia less than 50 mg/dl.
  • Rash:
  • Exfoliative or mucositis.
  • Cough:
  • Unremitting or bronchospasm uncontrolled by bronchodilator preventing more than 50 percent of delivered dose for more than 2 days.
  • Prior Medication:
  • Excluded within 14 days of study entry:
  • Systemic steroids higher than adrenal replacement doses.
  • Excluded within 6 weeks of study entry:
  • Another antiprotozoal regimen for this episode, whether therapeutic or prophylactic.
  • Sulfamethoxazole / trimethoprim.
  • Pyrimethamine.
  • Sulfadoxine / pyrimethamine.
  • Pentamidine.
  • Eflornithine.

Attachments

readout_NCT00000715_2024-02-21.pdf

4.5 MB

NCT00000715_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

New York, New York, United States

West Columbia, South Carolina, United States

Rochester, New York, United States

Chapel Hill, North Carolina, United States

Bronx, New York, United States

New Orleans, Louisiana, United States

Boston, Massachusetts, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0